ICURe validates the market and readies the team. PIPE is the next step: the commercialisation and capital pathway that begins where Exploit ends. The two programmes are sequential, not competing, and the join is the Exploit stage.
INNOVATE UK ICURe: validation & investor readiness → PIPE LAB TO IPO: capital & commercialisation
ICURe is the UK’s leading early-stage research pre-accelerator. By the time a team reaches Exploit, it has been through rigorous market testing, customer discovery, and is recommended for spin-out or licence: ICURe’s own materials describe these teams as significantly de-risked and ready for serious investor consideration.
Then the structured 12-week support of Exploit ends. The national gap has never been the quality of what ICURe produces. It is what happens next: sustained capital, embedded commercial capacity, and a credible route to scale and liquidity. That is precisely the PIPE Lab to IPO Pathway.
PIPE does not duplicate ICURe’s validation work, and PIPE does not compete for the same funding lane. PIPE is the commercialisation and capital pathway that picks up a venture at the point ICURe support ends, carrying it through venture formation, aligned investment, and on to PIPExchange and IPO.
ICURe and PIPE sit on the same continuum but do fundamentally different jobs. Seen side by side, the handover point is unambiguous.
Is there a market for this idea, and does the team have the founder instinct to pursue it.
How is the company built, funded, governed, and carried through to a credible exit.
Four staged programmes over roughly nine months: Engage (4 weeks), Discover (10 weeks), Explore (12 weeks, full time), Exploit (12 weeks).
An ongoing pathway with no fixed end point: QED-validated stage gates from Launch through to PIPExchange listing and IPO.
Programme support and, at Explore, up to £35,000 towards the Entrepreneurial Lead’s salary and costs. Exploit provides intensive non-financial support.
Up to €2m in initial capital through the PGF Launchpad and PIPE gDAO, deployed in KPI-gated tranches, with no upper limit on subsequent rounds.
Market validation, customer discovery, entrepreneurial training, and a recommendation for spin-out or licence.
An embedded PIPE Associate, structured venture formation, IP structuring, and a funded route to PIPExchange listing.
A recommendation to spin out or licence. Structured support then ends.
PIPExchange listing, full IPO, or acquisition: with board observation and licence support continuing throughout.
A team recommended for spin-out at Exploit has done the hard part: proving the market exists. What it has not yet done is build a fully governed company, secure patient capital aligned to research timelines, or establish a credible route to liquidity. PIPE exists for precisely that gap.
ICURe’s market testing feeds directly into the PIPE QED system, avoiding duplicated diligence. Your Exploit-stage evidence becomes the foundation of your Go/No-Go assessment, not a discarded artefact.
A PIPE Associate with relevant domain expertise joins the team at Launch, building the commercial pathway, structuring IP, and forming the venture alongside the academic founders.
Up to €2m in initial funding through the PGF Launchpad and PIPE gDAO, deployed against KPI-gated tranches: patient capital that understands frontier research does not move at venture-fund speed.
Validated, Associate-backed ventures progress to PIPExchange listing, securing further funding rounds with no upper limit, all the way to full IPO.
PIPE works within your institution’s existing IP framework and governance structures. No bypassing the TTO, no competing claim on the IP: PIPE extends what is already in motion.
The handover from ICURe Exploit into PIPE is designed to be clean: your team’s validated commercial case, customer evidence, and founder readiness carry straight into the PIPE pathway.
You have proven the market. Now build the company, with an operator beside you and capital that understands the timeline of frontier research.
See the next step at Exploit →Carry your ICURe spin-outs from formation to funding with no additional overhead and no equity grab. PIPE extends your existing process, it does not replace it.
Partner with PIPE →ICURe de-risks the science. PIPE delivers the capital pathway. A respectful, complementary fit that strengthens the visible outcomes of every ICURe cohort.
Start a conversation →ICURe-validated teams arrive at PIPE significantly de-risked, with customer evidence and founder readiness already demonstrated, then carried through QED validation and Associate-backed structuring.
Join the Investor Network →If your ICURe team has reached Exploit and been recommended to spin out or licence, the next conversation is with PIPE. Submit your innovation for QED assessment, or speak to the team directly about the handover.